To the Editor: The meta-analysis by the Collaborators on Trials of Lowering Glucose (CONTROL) Group [1] was a collaborative initiative established to address uncertainty about the effects of intensive glucose-lowering on the risk of major cardiovascular events. The four trials included in the meta-analysis were selected on the basis of prespecified trial inclusion criteria. The other important elements of the meta-analysis, including patient subgroups and the analytic strategy, were defined a priori and were not driven by the interim findings of our meta-analysis. As a result we believe we have provided a balanced interpretation of our findings. We agree with Drs Yudkin and Richter [2] that there is much to be gained from further interrogation of the trial data, particularly in relation to the different patient characteristics (e.g. disease history) and to the different drug regimens employed in each trial. We also agree that a meta-analysis that uses individual patient data is optimal for this purpose and allows the full exploration of as much phenotypic information as possible. Such an analysis is planned by the CONTROL Group once all data become available. In the interim, post hoc analyses [3] are not the optimal way of identifying how best to protect diabetic patients from stroke and coronary heart disease.
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